| 23008 |
House dust mite allergen extract |
Actair® |
Dermatophagoides pteronyssinus and Dermatophagoides farinae in equal parts (Actair®) is indicated for the treatment of moderate-to-severe house dust mite (HDM)–induced allergic rhinitis (AR) or rhinoconjunctivitis diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test [SPT] and/or specific immunoglobulin E [IgE]) in adolescents (aged 12-17 years) and adults. |
Rapid Review Complete |
24th February 2023 |
 |
| 20016 |
House Dust Mite Extract |
Acarizax ® |
Is indicated in adult patients (18-65 years) with HDM allergic asthma not well controlled by inhaled corticosteroids (ICS) and associated with mild to severe house dust mite allergic rhinitis. Diagnosis should be confirmed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE). |
NCPE Assessment Process Complete |
24th February 2023 |
|
| 20015 |
House Dust Mite Extract |
Acarizax ® |
For the treatment of adult patients (18-65 years) diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication. |
Assessment process complete |
30th April 2020 |
|
| - |
Human alpha1-proteinase inhibitor (A1PI) |
Prolastin® |
For long-term augmentation therapy in subjects with alpha1-proteinase inhibitor deficiency (phenotypes PiZZ, PiZ(null), Pi (null,null) and PiSZ) within the limits of moderate airflow obstruction (FEV1 35-60%) and the evaluation of the clinical condition (disability). |
Assessment process complete. |
8th June 2017 |
|
| - |
Human alpha1-proteinase inhibitor |
Respreeza® |
For maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null, null), PiSZ). Patients are to be under optimal pharmacologic and nonpharmacological treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency. |
Assessment process complete |
9th December 2016 |
|
| - |
Hyaluronic acid and co enzyme Q10 |
VisuXL® |
For the treatment of dry eye disease and the treatment of post-surgical intervention following elective surgery and trauma. |
Assessment process complete |
30th November 2017 |
|
| 21042 |
Hydrocortisone modified-release hard capsules |
Efmody® |
For the treatment of congenital adrenal hyperplasia in adolescents aged 12 years and over and adults. |
Assessment process complete |
4th November 2021 |
|
| - |
Hydroxycarbamide |
Siklos® |
For use in the prevention of painful, recurrent vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years of age suffering from symptomatic sickle-cell disease. |
Assessment process complete |
6th September 2011 |
|
| 20020 |
Hydroxycarbamide solution |
Xromi® |
For the prevention of vaso-occlusive complications of sickle cell disease in patients over two years of age. |
Assessment process complete |
14th May 2020 |
|
| - |
Modified Release Hydrocortisone |
Plenadren® |
For the treatment of adrenal insufficiency in adults. |
Assessment process complete |
1st January 2018 |
|
